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Long non-coding RNAs (ncRNAs) have added an unexpected layer of complexity in the
regulation of gene expression. Mounting evidence now links long ncRNAs to fundamental
biological processes such as development and differentiation, and recent research shows
important involvement of long ncRNAs in a variety of diseases including neurodegenerative
disorders, such as Parkinson’s, Alzheimer’s, spinocerebellar ataxia, and Huntington’s
diseases. Furthermore, long ncRNAs are speculated to be implicated in development of
psychiatric disorders such as schizophrenia and bipolar disorders. Long ncRNAs contribute
to these disorders in diverse ways, from regulation of transcription to modulation of RNA
processing and translation. In this review, we describe the diversemechanisms reported for
long ncRNAs, and discuss how they could mechanistically be involved in the development
of neurological disorders.
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INTRODUCTION
Recent technological advances such as next generation sequenc-
ing have revealed pervasive transcription of mammalian genomes
(Djebali et al., 2012). It has been reported that, whereas only a
small fraction of the human genome codes for proteins, 60% is
being transcribed into transcripts without protein coding capacity
(Derrien et al., 2012; Djebali et al., 2012). The majority of these
transcripts are referred to as long non-coding RNAs (ncRNAs).
The transcripts are often annotated as such judged by the lack of
an appreciable open reading frame (Derrien et al., 2012).
Although only a very small fraction of annotated long ncRNAs
has been well characterized, these examples show an involve-
ment at every level of the gene expression program (Ulitsky and
Bartel, 2013). Long ncRNAs have been reported to occur both
as spliced, polyadenylated, and capped transcripts often tran-
scribedbyRNApolymerase II, resemblingmRNAs in their physical
structure (Derrien et al., 2012), and to be non-polyadenylated
single-exon transcripts often involved in enhancer function (Orom
and Shiekhattar, 2013). In the current review, we focus on the for-
mer group of long ncRNAs, and provide an overview of their
involvement in neurological disorders.
A dominating view is that long ncRNAs often work in com-
plex with proteins to bring about regulatory functions (Rinn et al.,
2007; Tripathi et al., 2010; Bertani et al., 2011; Gong and Maquat,
2011; Wang et al., 2011; Lai et al., 2013) emphasizing one of the
areas of intensive research. Many long ncRNAs have been shown to
bind and guide chromatin remodeling factors to speciﬁc loci in the
genome (Rinn et al., 2007; Bertani et al., 2011; Wang et al., 2011).
Guttman et al. (2011) speculated that long ncRNAs can provide
targeted speciﬁcity of individual chromatin remodelers in different
cellular settings. Long ncRNAs have also been shown to bind more
chromatin remodelers at the same time to coordinate their activ-
ities (Tsai et al., 2010). In addition, there are several examples of
long ncRNAs regulating expression of genes post-transcriptionally
(Geisler and Coller, 2013; Ulitsky and Bartel, 2013).
A large fraction of tissue speciﬁc long ncRNAs are expressed in
the brain (Derrien et al., 2012). Furthermore, themajority of brain
speciﬁc long ncRNAs is speciﬁcally expressed in particular regions,
cell types or even subcellular compartments (Mercer et al., 2008,
2010; Derrien et al., 2012), suggesting speciﬁc regulatory roles in
subsets of specialized cells. For many of these long ncRNAs it has
been shown that they are functionally implicated in brain devel-
opment. Long ncRNA metastasis associated lung adenocarcinoma
transcript 1 works by regulating the activity of splicing factors,
and controling the expression of genes involved in synapse forma-
tion, density, and maturation (Bernard et al., 2010). Additionally,
a growing number of long ncRNAs has been shown to regulate
expression of genes/proteins with crucial roles in neurological dis-
orders (see Table 1 for an overview of long ncRNAs involved in
neurological disorders reviewed here in detail).
LONG ncRNAs REGULATE TRANSCRIPTION OF GENES
ASSOCIATED WITH NEUROLOGICAL DISORDER
Long ncRNA antisense non-coding RNA in the INK4 locus
(ANRIL) has been associated to hereditary cutaneous malignant
melanoma, prostate cancer and tumors of the neural system (Pas-
mant et al., 2011). Furthermore, genome wide association studies
have identiﬁed theANRIL gene as a risk locus for coronary disease,
intracranial aneurism, type 2 diabetes and several cancers includ-
ing glioma (Pasmant et al., 2011). ANRIL is an antisense RNA
transcript overlapping the INK4b/ARF/INK4a locus and partici-
pates directly in its epigenetic repression. The INK4b/ARF/INK4a
locus encodes for p15, p16, and the p14ARF protein, three major
players in cell fate determination (Pasmant et al., 2011). p15 and
p16 are major players in the retinoblastoma (Rb) signaling path-
way. Their inactivation in cells leads to inactivation of Rb, a
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Table 1 | Long ncRNAs involved in neurological disorders.
Long ncRNA Regulating Target Associated neurological disorder
ANRIL Transcription INK4b/ARF/INK4a locus Neural system tumors
BDNF-AS Transcription BDNF Huntington’s disease
ncRNA-a Transcription CMPK1, TAL1, AURKA Opitz–Kaveggia syndrome
Evf-2 Transcription Dlx5/6 Potentially Rett-syndrome, autism,
schizophrenia and epilepsy
HTTAS_v1 Transcription HTT Huntington’s disease
SCAANT1 Transcription Ataxin 7 Spinocerebellar ataxia 7
116HG Transcription Up-regulation of many
genes
Prader–Willi syndrome
ATXN8OS mRNA processing MBLN1 Spinocerebellar ataxia 8
17A mRNA processing GPR51 Alzheimer’s disease
Gomafu mRNA processing DISC1, ERBB4 Schizophrenia, behavioral
abnormalities
BACE1-AS mRNA stability BACE1 Alzheimer’s disease
BC200 Translation FMR1, PABP, HNRNPA2,
SYNCRIP
Alzheimer’s disease
Antisense Uchl1 Translation UCHL1 Parkinson’s disease
well-studied tumor suppressor protein, and progression through
the cell cycle. p14ARF activates Rb as well as the tumor suppressor
p53 by promoting the degradation of MDM2. Its inactivation can
also lead to cell cycle arrest (Pasmant et al., 2011). The components
of the INK4b/ARF/INK4a locus are repressed by both polycomb
repressive complex 1 (PRC1) andPRC2 repressive complex (Popov
and Gil, 2010). Yap et al. (2010) showed that by binding to the
CBX7 subunit of the PRC1 complex, ANRIL compromises its
capacity to repress the INK4b/ARF/INK4a locus and control senes-
cence inmouse embryonic ﬁbroblasts (Pasmant et al., 2011). These
data indicate that ANRIL regulates a gene locus that codes for
major players involved in control of cell cycle progression and
disease.
The antisense long ncRNA BDNF-AS regulates the expression
of the sense strand encoded brain derived neurotrophic factor
(BDNF). This protein belongs to a class of secreted growth factors
that are essential for neuronal growth,maturation, differentiation,
and maintenance. Its expression is impaired in neurodegenerative
as well as psychiatric disorders. For example, Huntington’s dis-
ease (HD) patients have reduced levels of BDNF. Recently it was
shown that knock-down of BDNF-AS resulted in upregulation of
BDNF (Modarresi et al., 2012). BDNF-AS mediates its effect via
PRC2. PRC2 represses gene expression through methylation of
Lysine 27 of histone H3 (H3K27me2/3) by its catalytic subunit
enhancer of zeste homolog 2 (EZH2) (Czermin et al., 2002). It
was shown that upon knock-down of BDNF-AS the occupancy
of EZH2 as well as H3K27me3 was reduced at the BDNF pro-
moter (Vashishtha et al., 2013). Thus, BDNF-AS inhibits BDNF
transcription by recruiting EZH2 to the BDNF promoter region
and in that way plays an important role in the development
of HD.
A recent study indicated that a subset of long ncRNAs, called
activating long ncRNAs (RNA-a), is associated with Opitz–
Kaveggia (also known as FG) syndrome, a X-linked intellectual
disability syndrome, characterized by various neuronal patholo-
gies as well as developmental abnormalities. It was shown that
the Mediator complex is recruited to ncRNA-a target genes via
its MED12 subunit, and regulates their expression (Figure 1).
Mediator complexes containingmissensemutantMED12 proteins
corresponding to FG syndrome fail to associate with ncRNA-a
(Lai et al., 2013), which might explain how these Mediator muta-
tions can cause disease. Mediator is a evolutionary conserved
multiprotein complex that controls transcription by RNA Poly-
merase II and acts as a key regulatory interface for the integration
of activating and repressing signals at promoters and distal
enhancers (Carlsten et al., 2013). The interaction of Mediator
and long ncRNAs is shown to be essential for recruitment of
the complex to the promoter of target genes and the H3S10
kinase activity of the Mediator complex, involved in its acti-
vating properties (Meyer et al., 2008). Loss of Mediator-ncRNA
interaction might be a possible contributing factor for the neu-
rological pathologies in FG patients. Taken together, ncRNA-a
could have a prominent role in gene activation and develop-
ment of FG syndrome due to its interaction with the Mediator
complex.
Evf-2 is a long ncRNA that is transcribed from an ultracon-
served enhancer in the Dlx-5/Dlx-6 locus that is important for
proper brain development. Evf-2 regulates transcription of this
unit by interacting with an activating as well as with a repress-
ing transcription factor. Evf-2 forms in vivo a complex with the
homeodomain containing protein Dlx-2 to activate transcrip-
tion of the Dlx5/6 enhancer (Feng et al., 2006). It also recruits
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FIGURE 1 |The mechanism of long ncRNAs involved in neurological
disorders. Long ncRNAs can regulate every level of gene expression.
Shown is a summary of selected long ncRNA functions discussed in
the review, that take place in different cellular compartments. Due to
space limitations not all long ncRNAs discussed in the review are
included.
the repressive methylation binding protein MECP2 to the same
locus. Furthermore, Evf2 prevents CpG methylation at the Dlx-
5/Dlx-6 locus, suggesting that methylated CpG sites are not
responsible for MECP2 recruitment (Berghoff et al., 2013). The
relationship between recruitment of MECP2 and prevention of
CpG methylation by Evf2 is not clear yet and needs to be fur-
ther explored. Nevertheless, loss of function of Evf2 leads to a
decrease in the number of GABAergic interneurons in the early
postnatal mouse hippocampus and dental gyrus. Malfunctions
in GABAergic interneurons have been implicated in a number
of neurological disorders including autism, schizophrenia and
epilepsy (Kohtz and Berghoff, 2010). Thus, it has been specu-
lated that Evf2 plays a role in the development of the described
disorders. Additionally, malfunctions in GABAergic interneurons
have been observed in Rett-syndrome, a X-linked neurological
disorder affecting females 1:10,000. Mecp2 knock-out mice as a
model for Rett-syndrome show extensive dysregulation of long
ncRNAs (Petazzi et al., 2013). As Evf-2 appears to control the
development of GABAergic interneurons, it is the subject of many
studies that will hopefully help to better understand the disor-
ders with malfunctions in these neurons and pinpoint to novel
therapeutics.
Long ncRNA HTTAS_v1 is regulating the expression of Hung-
tiontonin (HTT) and is potentially involved in the development
of HD (Chung et al., 2011). HTT is a protein that has a central
role in the development of HD that is believed to be partially
caused by trinucleotide repeat expansions in the gene coding for
HTT. HTTAS_v1 is transcribed antisense to HTT and one of its
exons includes the repeat. Overexpression of HTTAS_v1 leads to
a reduction in HTT transcript levels whereas depletion leads to
an increase in HTT transcript levels. This effect is dependent on
the repeat length. Furthermore, transcript levels of HTTAS_v1
are reduced in frontal cortex of patients who suffer from HD,
indicating that HTTAS_v1 might be an important long ncRNA
contributing to the development of this neurological disorder
(Chung et al., 2011).
Long ncRNA SCAANT1 is implicated in a type of polyglu-
tamine disorder, spinocerebellar ataxia type 7 (SCA7). Spinocere-
bellar ataxias are a group of neurological disorders affecting the
cerebellum. SCA7 is caused by CAG repeat expansion in ataxin-7
gene. Long ncRNA SCAANT1 is transcribed antisense to ataxin 7.
Lack of SCAANT1 leads to an increase in ataxin 7 transcription
causing a development of SCA7 in mice. Furthermore, proxi-
mal CTCF binding is required for SCAANT1 transcription. Thus,
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SCAANT1 acts a repressor of ataxin 7 transcription in a CTCF
dependent manner and is a potential player in development of
SCA7 (Sopher et al., 2011).
Long ncRNA 116HG has been shown to play a role in the devel-
opment of Prader–Willi syndrome (PWS) (Powell et al., 2013).
This syndrome is a neurological disorder caused by the paternal
deletions of some genes on chromosome 15, including the gene
that codes for the long ncRNA 116HG.Mice lacking this transcript
show most of the symptoms characteristic for PWS. Long ncRNA
116HG forms a cloud in the nuclei of both mouse and human
neurons (Powell et al., 2013). The cloud is formed at the site of the
transcription of this long ncRNA and this ncRNA co-puriﬁes with
RBBP5 a component of mixed lineage leukemia (MLL1) activating
chromatin remodeling complex. Since loss of this long ncRNA led
to an up-regulation of many genes Powell and colleagues suggested
that 116HG long ncRNA might act as a decoy for RBBP5 and in
this way disable it to activate transcription of these genes (Powell
et al., 2013). Additionally, metabolic analyses suggested that this
long ncRNA regulates diurnal energy expenditure of the brain. In
conclusion, long ncRNA 116HG regulates the expression of many
genes potentially through interacting with RBBP5 and might help
to balance energy consumption.
LONG ncRNAs REGULATE PROCESSING OF mRNAs
ATXN8OS is a long ncRNA localized in GABAergic interneurons
(Moseley et al., 2006) and plays a signiﬁcant role in the devel-
opment of SCA8, a type of ataxia caused by repeat expansion
in ATXN8OS and ATXN8. The ATXN8OS ncRNA shares a bidi-
rectional promoter with ATXN8 that encodes a protein known
to contribute to the development of SCA8. Both the ATXN8OS
and ATXN8 in SCA8 undergo a gain of function due to (CTG)n
repeat expansions (Moseley et al., 2006; Daughters et al., 2009).
Long ncRNA transcripts with trinucleotide expansion co-localize
in GABAergic neurons with the muscleblind-like splicing regula-
tor 1 (MBLN1) and cause changes in its localization and splicing
regulatory activity. As a consequence, GABA-A transporter 4
RNA undergoes alternative splicing leading to loss of GABAergic
inhibition, characteristic for SCA8 (Sopher et al., 2011).
A potential contributor to the development of Alzheimer’s dis-
ease (AD) is long ncRNA 17A (Massone et al., 2011). This long
ncRNA is transcribed by RNA polymerase III (Pol III) and is an
antisense transcript of humanG-protein-coupled receptor 51 gene
(GPR51; Massone et al., 2011). Depending on alternative splic-
ing events, this gene codes for a functional GABA B2 receptor
or unfunctional GABA R2. In a human neuroblastoma cell line
stable expression of long ncRNA 17A induced the production of
unfunctional alternative splice isoforms for GABA R2, leading to
the abolishment of GABA B2 intracellular signaling and secre-
tion of amyloid-β peptide, characteristic for AD (Kim et al., 2013).
Similarly, in cerebral cortex of AD patients 17A is upregulated and
the functional GABA B2 receptor could not be detected suggesting
that 17A and abolishment of GABA B2 signaling might play a role
in the development of AD (Massone et al., 2011).
It has been shown that long ncRNA Gomafu (MIAT, RNCR2)
plays a role in retinal cell development, brain development and
post-mitotic neuronal function (Tsuiji et al., 2011; Barry et al.,
2013). It localizes to speciﬁc subset of neurons in adult mice,
including the CA1 region of the hippocampus and large corti-
cal neurons. It is localized in the compartment of the nucleus
enriched in splicing factors (Tsuiji et al., 2011; Barry et al., 2013).
This non-coding RNA has a distinctive feature: tandem repeats
of UACUAAC, a conserved intron branch point that binds to
the SF1 splicing factor (Tsuiji et al., 2011). Gomafu also binds
directly two additional splicing factors QKI and SRSF1. Dysregu-
lation of this long ncRNA leads to alternative splicing patterns
of DISC1 and ERBB4 (Figure 1). These alternative splicing
patterns are similar to those observed in schizophrenic dis-
order. Furthermore, Gomafu is dysregulated in the cortex of
schizophrenic subjects. Collectively these results indicate that
Gomafu may contribute to development of schizophrenia dis-
order (Barry et al., 2013). In addition, Gomafu is upregulated
in the region of the brain involved in behavior and addiction
of cocaine and heroine users, suggesting that Gomafu might
also have a role in behavioral abnormalities (Albertson et al.,
2006).
With the great diversity of alternative splice forms in the human
genome many more examples of long ncRNAs regulating alterna-
tive splicing of both mRNAs and other RNA species should be
expected to be identiﬁed and characterized soon.
LONG ncRNAs REGULATE mRNA STABILITY
Another long ncRNA demonstrated to play a role in AD is
BACE1-AS. This long ncRNAs is transcribed antisense to β-
secretase-1 protein (BACE1) and regulates BACE1 mRNA stability
(Faghihi et al., 2008). BACE1 is an enzyme that generates amyloid-
β that clusters in amyloid plaques that are a histological hallmark
of AD. Recently, a study in mouse AD model revealed that in
this clustered form amyloid-β triggers the erosion of synaptic
connections between neurons which are crucial for proper func-
tioning of the brain and AD pathophysiology (Kim et al., 2013).
Upon stress stimuli BACE1-AS gets upregulated and increases
BACE1 mRNA stability by duplexing with BACE1 mRNA, lead-
ing to the generation of additional BACE1 enzyme and amyloid-β
(Figure 1; Faghihi et al., 2008). The levels of BACE1-AS are ele-
vated in subjects with AD and its in vivo knock-down in mouse
brain led to the downregulaton of BACE1 protein levels, reduction
in amyloid-β synthesis and aggregation in the brain, signify-
ing the importance of BACE1-AS for the development of AD
(Modarresi et al., 2011).
This is an example of a long ncRNA that is reported to be acting
without a protein partner, and thus represents an alternative view
on the mechanism of long ncRNAs. This could be a more general
property of a class of long ncRNAs that should be studied more
extensive in future research.
LONG ncRNAs REGULATE TRANSLATION
BC1 in rats and BC200 in humans, are two long ncRNAs that
are compartmentalized in synaptodendrites as ribonucleoprotein
particles contributing to the regulation of local protein synthesis.
BC200 seems to be linked to AD development; patients suffer-
ing from AD show higher expression of BC200 in the affected
area of their brain (Brodmann’s area 9), compared to same aged
healthy controls. Furthermore, the levels of BC200 increase with
the severity of AD in this area of the brain. Additionally, in
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advanced stages of AD BC200 mislocalized to the perikaryon
(Mus et al., 2007). BC200 has been suggested to modulate gene
expression at the translational level by interacting with differ-
ent proteins: fragile X mental retardation protein (a translational
repressor), poly(A)-binding protein 1 (a translation initiation reg-
ulator), heterogeneous nuclear ribonucleoprotein A2 (involved
in transport of mRNAs in neurons), and synaptotagmin bind-
ing cytoplasmic RNA interacting protein (also involved in mRNA
transport and potentially in local protein synthesis) (Muddashetty
et al., 2002; Muslimov et al., 2006; Duning et al., 2008). Over-
expression, mislocalization, as well as interaction with proteins
involved in local protein synthesis and trafﬁcking in neurons
suggest BC200 to be an important player in the development
of AD.
A long ncRNA transcribed antisense of the mouse ubiqui-
tin carboxy-terminal hydrolase L1 (Uchl1) gene can induce the
translation of Uchl1. Human UCHL1 is a neuron-restricted pro-
tein that acts as a de-ubiquitinating enzyme, ubiquitin ligase
or monoubiquitin stabilizer, and its inactivation was reported
in both AD and Parkinson’s disease (PD) patients. Overexpres-
sion of antisense Uchl1 led to an increase in the abundance of
UCHL1 protein without affecting its mRNA levels. Only a par-
tial overlap between the long ncRNA and mRNA is required
for this activity. Uchl1 mRNA localizes predominantly in the
cytoplasm whereas the antisense ncRNA is enriched in the
nucleus of dopaminergic neurons. When dopaminergic cells
are treated with an mTOR inhibitor, antisense Uchl1 relocal-
izes to the cytoplasm, triggers the binding of Uchl1 mRNA to
polysomes and an increase in UCHL1 protein level is observed
(Figure 1) (Carrieri et al., 2012). Since in genetic and neuro-
chemical models of PD,mTOR1 inhibition protects dopaminergic
neurons from apoptosis it is possible that the UCHLE-ncRNA-
mTOR1 interplay might be important for the development
of PD.
OTHER LONG ncRNAs THAT ARE POTENTIALLY INVOLVED IN
NEUROLOGICAL DISORDERS
Many other long ncRNAs are suspected to be involved in neuro-
logical disorders. Some of them are: TUG1 is upregulated in HD
patients; PINK1-AS is potentially involved in the development
of PD; Sox2OT whose gene carries the important regulator of
neurogenesis gene in an alternatively spliced intron might serve
as a biomarker for AD since it’s expressed exclusively in early
stages of AD; Ube 3a–AS has been implicated in Angelman’s syn-
drome (genetic disorder that causes developmental disabilities and
neurological problems) since it was suggested that it might regu-
late the expression of Ube3a that is mutated or deleted in this
syndrome; ASFMR1, FMR4, and FMR6 long ncRNAs are down-
regulated in neurons of patients suffering from fragile X syndrome
(genetic disorder that causes a range of developmental problems
including learning disabilities and cognitive impairment) but not
in healthy individuals and thus might play a role in develop-
ment of this disorder; DISC2 long ncRNA might contribute to
the development of schizophrenia disorder since it is disrupted
by a translocation in this disorder (Pastori and Wahlestedt, 2012;
Fenoglio et al., 2013; Ng et al., 2013; Pastori et al., 2014). Addtion-
aly, Lipovich et al. (2013) identiﬁed eight human brain speciﬁc
long ncRNAs whose expression is changing in an age-related
manner.
Long ncRNA NEAT1_2 has been shown to contribute to the
development of amyotrophic lateral sclerosis (ALS), a motor neu-
ron disease (Nishimoto et al., 2013). One of the proteins mutated
and contributing to the development of ALS are two DNA/RNA
binding proteins: TAR DNA-binding protein-43 (TDP-43) and
fused in sarcoma/translocated in liposarcoma (FUS/TLS; Lagier-
Tourenne and Cleveland, 2009). Recently it was showed that both
TDP-43 and FUS/TLS are bound by and co-localize with the long
ncRNA NEAT1_2. This long ncRNA is essential for the formation
of nuclear bodies called paraspeckles and was shown to be upreg-
ulated in human motor neurons in early stage of ALS (Nishimoto
et al., 2013). Thus, NEAT1_2 might contribute to the develop-
ment of early stage of ALS through interaction with TDP-43 and
FUS/TLS.
Long ncRNAs could also be involved in the development of
HD, in which long ncRNAs HAR1F and HAR1R are affected
(Pollard et al., 2006). Human accelerated regions (HARs) are fast
evolving non-coding sequences in the human brain often found
in the proximity of neurodevelopmental genes like GATA3. It
was suggested that they might potentially participate in unique
human brain functions (Pollard et al., 2006). Of these the most
dramatic accelerated changes were found in the HAR1 locus
that codes for the two long ncRNAs HAR1F and HAR1R (Pol-
lard et al., 2006). The expression of both can be repressed by
the RE-1-silencing transcriptional factor (REST) that patholog-
ically (in HD) translocates to the nucleus and represses important
neuronal genes in neuronal cells (Johnson et al., 2010). Future
studies are needed to shed light on the mechanism of HAR1
long ncRNAs and their precise contribution to the development
of HD.
PERSPECTIVES
The repertoire of diverse functions of long ncRNAs has con-
tributed to an increased understanding of gene regulation. Long
ncRNAs are involved in brain functions in both normal and dis-
eased state, adding an additional layer of complexity to brain
function. The number of long ncRNAs has been proposed to
correlate with the complexity of the organism (Taft et al., 2007),
and it is tempting to speculate that brain speciﬁc long ncRNAs
might be evolutionary innovations that participate in humanbrain
function.
The fact that a long ncRNA is differentially expressed in the
healthy vs the disease brain or its expression correlates with a
protein known to be involved in brain disorders could be due to
various reasons that are unrelated to the disease or just unspe-
ciﬁc side-effects. One way to study the functional relevance of
long ncRNAs during brain development and in neurological disor-
ders in physiological conditions is to generate mouse models with
inactivated speciﬁc long ncRNA genes. Analysis of these mutant
strains could demonstrate the distinct in vivo roles during embry-
onic development and disease. Further investigations of the long
ncRNA mechanisms will help to better understand how the brain
functions and how disorders develop, with the potential to fur-
ther drug development based on manipulation of long ncRNA
expression.
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